 Celldex Therapeutics Inc NASDAQ: CLDX will expand the clinical development of CDX-0159 into prurigo nodularis PN, a chronic skin disease characterized by the development of hard, intensely itchy pruritic nodules on the skin. In a Phase 1a single-dose, healthy volunteer study, CDX-0159 demonstrated durable plasma tryptase reductions indicative of systemic mast cell suppressionablation. 